21 Mar 2025 • Pediatric patients (ages 3-17) with atopic dermatitis (AD) treated with dupilumab face an increased risk of developing dupilumab-associated ocular surface disease (DAOSD).

In a study, one-third of the patients experienced symptoms such as pruritus (75.0%), redness (72.2%), and tearing (58.3%), with tarsal conjunctivitis present in all, requiring treatment. Elevated serum IgE levels (≥ 3000 kU/L) corresponded with increased risk of DAOSD (OR 4.65). Among those affected, 30.6% required ocular anti-inflammatory therapy.

This study highlights the importance of monitoring ocular symptoms in pediatric patients with atopic dermatitis on dupilumab to enable early intervention.

Source: WILEY | Read Full Story